WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: A children's oncology group study

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 698-703

  Perlman, Elizabeth J ^a   Grundy, Paul E ^a   Anderson, James R ^a   Jennings, Lawrence J ^a   Green, Daniel M ^a   Dome, Jeffrey S ^a   Shamberger, Robert C ^a   Ruteshouser, E Cristy ^a   Huff, Vicki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CTNNB1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; WT1 PROTEIN; WTX PROTEIN;

ARTICLE; CHILD; CHROMOSOME 11P; GENE MUTATION; GENOME IMPRINTING; HETEROZYGOSITY LOSS; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; METHYLATION; MICROSATELLITE MARKER; MOLECULAR IMPRINTING; NEPHRECTOMY; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SURGICAL TECHNIQUE; VERY LOW RISK WILMS TUMOR;

CHROMOSOMES, HUMAN, PAIR 11; GENES, WILMS TUMOR; HUMANS; INFANT; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 79952173570     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.5192     Document Type: Article

References (24)

1. Green DM, Breslow NE, Beckwith JB, et al: Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 19:3719-3724, 2001 (Pubitemid 32844783)
2. Shamberger RC, Anderson J, Breslow N, et al: Long term outcomes of infants with very low risk Wilms tumor treated with surgery alone on National Wilms Tumor Study-5. Ann Surg 251:555-558, 2010
3. Sredni S, Gadd S, Huang CC, et al: Subsets of very low risk Wilms tumors show distinctive gene expression, histologic, and clinical features. Clin Cancer Res 15:6800-6809, 2009
4. Huff V: Wilms tumor genetics. Am J Med Genet 79:260-267, 1998
5. Gessler M, Konig A, Arden K, et al: Infrequent mutation of the WT1 gene in 77 Wilms' Tumors. Hum Mutat 3:212-222, 1994 (Pubitemid 24122238)
6. Varanasi R, Bardeesy N, Ghahremani M, et al: Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci U S A 91:3554-3558, 1994 (Pubitemid 24139468)
7. Ruteshouser EC, Hendrickson BW, Colella S, et al: Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors. Genes Chromosomes Cancer 43:172-180, 2005 (Pubitemid 40570737)
8. Grundy PE, Breslow NE, Li S, et al: Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312-7321, 2005 (Pubitemid 46205952)
9. Natrajan R, Little SE, Sodha N, et al: Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 211:52-59, 2007 (Pubitemid 46092029)
10. Ruteshouser EC, Robinson SM, Huff V: Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47:461-470, 2008
11. Getman ME, Houseal TW, Miller GA, et al: Comparative genomic hybridization and its application to Wilms' tumorigenesis. Cytogenet Cell Genet 82:284-290, 1998 (Pubitemid 29002483)
12. Steenman M, Redeker B, de Meulemeester M, et al: Comparative genomic hybridization analysis of Wilms tumors. Cytogenet Cell Genet 77:296-303, 1997 (Pubitemid 27370954)
13. Maiti S, Alam R, Amos CI, et al: Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60:6288-6292, 2000
14. Li CM, Kim CE, Margolin AA, et al: CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165:1943-1953, 2004
15. Fukuzawa R, Heathcott RW, Sano M, et al: Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol 7:125-137, 2004 (Pubitemid 38715332)
16. Green DM, Jaffe N: The role of chemotherapy in the treatment of Wilms tumor. Cancer 44:52-57, 1979 (Pubitemid 9234909)
17. Green DM, Breslow NE, Beckwith JB, et al: Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms tumors: A report from the National Wilms Tumor Study. J Clin Oncol 11:91-95, 1993 (Pubitemid 23059980)
18. Folgueira MA, Carraro DM, Brentani H, et al: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11:7434-7443, 2005 (Pubitemid 41507704)
19. Breslow NE, Norris R, Norkool PA, et al: Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: A report from the National Wilms Tumor Study Group. J Clin Oncol 21:4579-4585, 2003 (Pubitemid 46594030)
20. Dao DD, Schroeder WT, Chao LY, et al: Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor. Am J Hum Genet 41:202-217, 1987 (Pubitemid 17145619)
21. Fukuzawa R, Breslow NE, Morison IM, et al: Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 363:446-451, 2004 (Pubitemid 38210061)
22. Bjornsson HT, Brown LJ, Fallin MD, et al: Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 99:1270-1273, 2007 (Pubitemid 47299905)
23. Grundy PE, Telzerow PE, Breslow N, et al: Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 54:2331-2333, 1994 (Pubitemid 24138720)
24. Pritchard-Jones K, Kelsey A, Vujanic G, et al: Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: A study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol 21:3269-3275, 2003 (Pubitemid 46606260)